New combo therapy aims to keep stomach cancer from returning
NCT ID NCT07263386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (SOX) can help prevent stomach cancer from coming back after surgery. It involves 460 adults with a specific type of advanced stomach cancer (PD-L1 positive, stage N3). Participants are randomly assigned to receive either the standard chemo alone or the chemo plus sintilimab, and researchers will track how long they stay cancer-free.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
- Can stomach cancer surgery also tame diabetes?
- Can a modified stomach bypass speed up recovery in advanced gastric cancer?